cvdol
nenurodyta - karvedilolis - plėvele dengtos tabletės - 6,25 mg - carvedilol
namuscla
lupin europe gmbh - mexiletine hydrochloride - myotonic sutrikimai - Širdies terapija - namuscla fluorouracilu ir simptominis gydymas myotonia suaugusiųjų pacientų su ne dystrophic myotonic sutrikimai.
gripex
us pharmacia sp. z o.o. - paracetamolis/pseudoefedrino hidrochloridas/dekstrometorfano hidrobromidas - plėvele dengtos tabletės - 325 mg/30 mg/10 mg - paracetamol, combinations excl. psycholeptics
tenaxum
les laboratoires servier - rilmenidinas - tabletės - 1 mg - rilmenidine
hipokin
g.l. pharma gmbh - tiapridas - tabletės - 100 mg - tiapride
veltassa
vifor fresenius medical care renal pharma france - patiromer sorbitex kalcio - hiperkalemija - narkotikų gydymo hyperkalemia ir hyperphosphatemia - veltassa skiriama hiperkalemijos gydymui suaugusiesiems.
ryeqo
gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyoma - hipofizės ir hipotalaminiai hormonai ir analogai - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
digoxin wzf polfa
warszawskie zakłady farmaceutyczne polfa s.a. - digoksinas - tabletės - 250 µg; 0,25 mg - digoxin
tiapridal
neuraxpharm arzneimittel gmbh - tiapridas - tabletės - 100 mg/2 ml - tiapride
jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritas, reumatas - imunosupresantai - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.